Literature DB >> 28860581

FDA OKs first in vitro route to expanded approval.

Katie Kingwell.   

Abstract

Mesh：

Substances：

Year:  2017        PMID： 28860581     DOI： 10.1038/nrd.2017.140

Source DB:  PubMed          Journal:  Nat Rev Drug Discov        ISSN： 1474-1776            Impact factor:   84.694


× No keyword cloud information.
  4 in total

1.  Net benefit of ivacaftor during prolonged tezacaftor/elexacaftor exposure in vitro.

Authors:  Ciaran A Shaughnessy; Pamela L Zeitlin; Preston E Bratcher
Journal:  J Cyst Fibros       Date:  2022-03-02       Impact factor: 5.527

2.  Folding and Misfolding of Human Membrane Proteins in Health and Disease: From Single Molecules to Cellular Proteostasis.

Authors:  Justin T Marinko; Hui Huang; Wesley D Penn; John A Capra; Jonathan P Schlebach; Charles R Sanders
Journal:  Chem Rev       Date:  2019-01-04       Impact factor: 60.622

3.  Elexacaftor is a CFTR potentiator and acts synergistically with ivacaftor during acute and chronic treatment.

Authors:  Ciaran A Shaughnessy; Pamela L Zeitlin; Preston E Bratcher
Journal:  Sci Rep       Date:  2021-10-06       Impact factor: 4.379

4.  The impact of FDA and EMA regulatory decision-making process on the access to CFTR modulators for the treatment of cystic fibrosis.

Authors:  Enrico Costa; Silvia Girotti; Francesca Pauro; Hubert G M Leufkens; Marco Cipolli
Journal:  Orphanet J Rare Dis       Date:  2022-05-07       Impact factor: 4.303
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.